Kuwabara Anne, Miller Olson Emily, Stanek Jeremy L
Stanford Sports Medicine, 6121 Hollis St., Ste 900, Emeryville, CA 94608, USA.
Med Probl Perform Art. 2024 Dec;39(4):155-161. doi: 10.21091/mppa.2024.04018.
While anecdotal reports of the use of performance-enhancing medications to curb anxiety in performing artists abound, there has been no research to date assessing the prevalence of usage and attitudes towards use amongst the artists themselves. The objective of this study was to evaluate the perceptions, acquisition, and use of potentially performance-enhancing medications (benzodiazepines, beta-blockers, and cannabinoids) in the performing artist community to clarify the use of these medications to improve patient counseling and patient safety.
Cross-sectional survey.
Anonymous survey administered through an online platform (REDCap).
None.
Musicians who are members of or perform in member groups of the American Federation of Musicians, National Association of Schools of Music, Regional Orchestra Players Association, and the International Conference of Symphony and Opera Musicians.
Prevalence of medication usage, subject perceptions of usage, and subject acquisition of medications.
A total of 311 subjects participated in the study. The mean age was 45.6 years, 52% male and 47% female. Forty percent are full-time ensemble musicians, with most being orchestral musicians in a stand-alone orchestra. Fifty-seven percent of subjects take beta-blockers when auditioning for a job, 51% take beta-blockers for performances, and 19% for solo situations. Fewer musicians take benzodiazepines and cannabis products to help with anxiety. Thirty-two percent, 22%, and 17% felt beta-blockers, benzodiazepines, and cannabis were performance-enhancing respectively, but less than 10% felt use was unethical.
The results of this study demonstrate current use patterns of beta-blockers, benzodiazepines, and cannabis-containing products in the musician population. Beta-blockers appear to be well tolerated and most frequently used for performance anxiety.
虽然关于使用增强表演效果药物来缓解表演艺术家焦虑的轶事报道比比皆是，但迄今为止尚无研究评估这些药物在艺术家群体中的使用 prevalence 以及他们对使用这些药物的态度。本研究的目的是评估表演艺术家中潜在的增强表演效果药物（苯二氮卓类药物、β受体阻滞剂和大麻素）的认知、获取和使用情况，以阐明这些药物的使用情况，从而改善患者咨询和患者安全。
横断面调查。
通过在线平台（REDCap）进行匿名调查。
无。
美国音乐家联合会、全国音乐学校协会、地区管弦乐队演奏者协会以及交响乐团和歌剧音乐家国际会议的成员或在其成员团体中表演的音乐家。
药物使用 prevalence、受试者对使用的认知以及受试者获取药物的情况。
共有311名受试者参与了研究。平均年龄为45.6岁，男性占52%，女性占47%。40%是全职合奏音乐家，大多数是独立管弦乐队中的管弦乐音乐家。57%的受试者在试镜时服用β受体阻滞剂，51%在表演时服用β受体阻滞剂，19%在独奏时服用。较少有音乐家服用苯二氮卓类药物和大麻产品来缓解焦虑。分别有32%、22%和17%的人认为β受体阻滞剂、苯二氮卓类药物和大麻能增强表演效果，但不到10%的人认为使用这些药物是不道德的。
本研究结果表明了音乐家群体中β受体阻滞剂、苯二氮卓类药物和含大麻产品的当前使用模式。β受体阻滞剂似乎耐受性良好，最常用于缓解表演焦虑。
